Alan B. Glassberg
Corporate Officer/Principal presso The University of California, San Francisco
Posizioni attive di Alan B. Glassberg
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/1970 | - |
Storia della carriera di Alan B. Glassberg
Precedenti posizioni note di Alan B. Glassberg
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BIOGEN INC. | Direttore/Membro del Consiglio | 01/01/1997 | 01/06/2009 |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Direttore/Membro del Consiglio | 01/01/1997 | 31/12/2008 |
| PONIARD PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 24/08/2006 | 15/03/2007 |
Aravive Biologics, Inc.
 Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Direttore/Membro del Consiglio | - | - |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Corporate Officer/Principal | 16/12/2010 | - |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Direttore/Membro del Consiglio | 01/01/1997 | - |
Formazione di Alan B. Glassberg
| College of Charleston | Undergraduate Degree |
| Medical University of South Carolina | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 10 |
Posizioni
| Director/Board Member | 4 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 4 |
| Finance | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- Alan B. Glassberg
- Esperienza
